Olivier Cussenot
Overview
Explore the profile of Olivier Cussenot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
317
Citations
8328
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Barral M, Lassalle L, Gardavaud F, Lehrer R, Haffaf I, Agbonon R, et al.
J Vasc Interv Radiol
. 2023 Nov;
35(3):409-415.
PMID: 38008376
Purpose: To evaluate the impact of virtual injection software (VIS) use during cone-beam computed tomography (CT)-guided prostatic artery embolization (PAE) on both patient radiation exposure and procedural time. Materials And...
12.
Beijert I, Hentschel A, Brundl J, Comperat E, Plass K, Rodriguez O, et al.
Int Urol Nephrol
. 2023 Nov;
56(4):1323-1333.
PMID: 37980689
Purpose: A re-transurethral resection of the bladder (re-TURB) is a well-established approach in managing non-muscle invasive bladder cancer (NMIBC) for various reasons: repeat-TURB is recommended for a macroscopically incomplete initial...
13.
Wang A, Shen J, Rodriguez A, Saunders E, Chen F, Janivara R, et al.
Nat Genet
. 2023 Nov;
55(12):2065-2074.
PMID: 37945903
The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-ancestry...
14.
15.
Figiel S, Yin W, Doultsinos D, Erickson A, Poulose N, Singh R, et al.
Mol Cancer
. 2023 Oct;
22(1):162.
PMID: 37789377
Genetic signatures have added a molecular dimension to prognostics and therapeutic decision-making. However, tumour heterogeneity in prostate cancer and current sampling methods could confound accurate assessment. Based on previously published...
16.
Gaye O, Fall C, Jalloh M, Faye B, Jobin M, Cussenot O
Curr Opin Urol
. 2023 Sep;
33(6):437-444.
PMID: 37678152
Purpose Of Review: Urine volatile organic compound (VOC) testing for early detection of urological cancers is a minimally invasive and promising method. The objective of this review was to present...
17.
Cussenot O, Fromont G, Cancel-Tassin G, Hamdy F, Martin R
Curr Opin Urol
. 2023 Aug;
33(6):421-427.
PMID: 37555785
Purpose Of Review: Many studies on epidemiology of prostate cancer (PCa) are based on a diagnosis of PCa using PSA (prostate-specific antigen) level. However, biases can distort the interpretation of...
18.
Campedel L, Comperat E, Cancel-Tassin G, Varinot J, Pfister C, Delcourt C, et al.
BJU Int
. 2023 Jul;
132(5):581-590.
PMID: 37488983
Objective: To evaluate the prognostic value of programmed death ligand-1 (PD-L1) and programmed death-1 (PD-1) expression in patients with upper tract urothelial carcinoma (UTUC). Patients And Methods: A retrospective multicentre...
19.
Hess T, Maj C, Gehlen J, Borisov O, Haas S, Gockel I, et al.
EBioMedicine
. 2023 Jul;
94:104709.
PMID: 37480624
No abstract available.
20.
Cussenot O, Cancel-Tassin G, Rao S, Woodcock D, Lamb A, Mills I, et al.
BJU Int
. 2023 Jul;
132(5):472-484.
PMID: 37410655
Objective: To review the current status of germline and somatic (tumour) genetic testing for prostate cancer (PCa), and its relevance for clinical practice. Methods: A narrative synthesis of various molecular...